Gorilla Technology (Nasdaq: GRRR) has repurchased $5.4M of shares to date under its $10M buyback program, with $1.8M executed in April and May alone—demonstrating strong confidence in its market value. Insider ownership now nears 20%, signaling deep alignment with shareholder interests as the company prepares to announce Q1 2025 earnings and continued expansion across global smart infrastructure markets.

Connect Biopharma (Nasdaq: CNTB) presented compelling new data at ATS 2025 highlighting rademikibart’s rapid FEV1 improvements—often within 24 hours—and significant reductions in acute exacerbations in asthma patients, supporting its Phase 2 trials in asthma and COPD. Structural analyses show rademikibart offers enhanced IL-4Rα inhibition and a superior safety profile compared to dupilumab, reinforcing its potential as a best-in-class treatment for over 2 million U.S. patients with inflammation-driven respiratory conditions.

bioAffinity Technologies (Nasdaq: BIAF) has appointed Dr. Gordon Downie, a seasoned pulmonologist and early lung cancer diagnostics expert, as Chief Medical Officer to lead the clinical expansion of its flagship test, CyPath® Lung. With over 30 years in pulmonary medicine and a track record of innovation, Dr. Downie brings critical expertise as the company scales its AI-driven, noninvasive lung cancer detection platform.

XTI Aerospace (Nasdaq: XTIA) reported major Q1 milestones, including FAA acceptance of its TriFan 600 Type Certification application and key engineering upgrades, as it preps for a pre-sales relaunch. The company also eliminated legacy debt and stock-based obligations, boosting cash to $8M and net working capital by $8.9M—paving the way for growth in the xVTOL space and positioning TriFan 600 as a game-changer in regional air mobility.